| Literature DB >> 36249271 |
Milan N Parikh1, Cole Brokamp1,2, Erika Rasnick1, Lili Ding1,2, Tesfaye B Mersha2,3, Katherine Bowers1,2, Alonzo T Folger1,2.
Abstract
Exposure to particulate matter with an aerodynamic diameter smaller than 2.5 microns (PM2.5) can affect birth outcomes through physiological pathways such as inflammation. One potential way PM2.5 affects physiology could be through altering DNA methylation (DNAm). Considering that exposures during specific windows of gestation may have unique effects on DNAm, we hypothesized a timing-specific association between PM2.5 exposure during pregnancy and DNAm in the neonatal epithelial-cell epigenome.Entities:
Keywords: DNA methylation; Fine particulate matter; Prenatal exposure
Year: 2022 PMID: 36249271 PMCID: PMC9556110 DOI: 10.1097/EE9.0000000000000227
Source DB: PubMed Journal: Environ Epidemiol ISSN: 2474-7882
Study sample characteristics
| Characteristics | Included subjects (n = 91) |
|---|---|
| Maternal factors | |
| Enrollment age (years); mean (SD) | 22.6 (4.1) |
| Race, n (%) | |
| Black | 50 (54.9) |
| White | 33 (36.3) |
| Other | 8 (8.8) |
| Child factors | |
| Sex; n (%) | |
| Female | 42 (46.2) |
| Male | 49 (53.8) |
| Gestational age at birth (weeks); mean (SD) | 38.9 (1.6) |
Figure 1.Manhattan plots for the association between DNA methylation at each studied CpG site and average PM2.5 over trimesters 1 and 2 of pregnancy adjusted for specified covariates. The vertical axis plots the negative log10 P value for each association. The Bonferroni cutoff for significance is denoted by the horizontal red line.
Ten CpG sites with the lowest P values from each EWA
| Trimester 1 | ||||||
|---|---|---|---|---|---|---|
| CpG site | Chr | Gene | Location | M coefficient |
| β coefficient (95% CI) |
| cg14305641 | 19 |
| 3′ UTR | 0.792 | 4.62 × 10–07 | 0.015 (0.008, 0.022) |
| cg16668903 | 5 |
| Body | 0.714 | 6.83 × 10–07 | 0.013 (0.007, 0.018) |
| cg10940724 | 9 |
| TSS1500 | 1.615 | 1.82 × 10–06 | 0.142 (0.086, 0.198) |
| cg10419550 | 8 | Intergenic | Intergenic | 1.094 | 3.17 × 10–06 | 0.175 (0.109, 0.240) |
| cg13898459 | 19 |
| TSS1500 | 0.949 | 3.92 × 10–06 | 0.211 (0.134, 0.289) |
| cg16180217 | 3 |
| TSS200 | 0.598 | 4.56 × 10–06 | 0.132 (0.076, 0.188) |
| cg00672633 | 6 | Intergenic | Intergenic | 1.758 | 4.72 × 10–06 | 0.404 (0.241, 0.568) |
| cg25799969 | 2 |
| 5′ UTR; 1st Exon | 1.758 | 6.38 × 10–06 | 0.167 (0.088, 0.246) |
| cg07309144 | 17 |
| Body | 1.929 | 8.05 × 10–06 | 0.198 (0.111, 0.286) |
| cg02330710 | 1 |
| Body | 1.414 | 8.59 × 10–06 | 0.343 (0.199, 0.486) |
| Trimester 2 | ||||||
| CpG site | Chr | Gene | Location | M coefficient |
| β coefficient (95% CI) |
| cg11845050 | 22 |
| TSS200 | 0.766 | 1.30 × 10–07 | 0.033 (0.022, 0.044) |
| cg13804427 | 10 |
| 5′ UTR | 0.931 | 6.73 × 10–06 | 0.056 (0.037, 0.075) |
| cg02397114 | 17 |
| TSS200 | 0.673 | 7.72 × 10–06 | 0.023 (0.013, 0.032) |
| cg10180496 | 4 |
| TSS1500; 5′ UTR; TSS200; Body | 1.450 | 8.83 × 10–06 | 0.101 (0.061, 0.142) |
|
| TSS1500 | |||||
| cg10156714 | 20 |
| Body | 0.635 | 8.99 × 10–06 | 0.024 (0.016, 0.032) |
| cg25967419 | 6 |
| TSS1500, TSS200 | 1.872 | 1.09 × 10–05 | 0.045 (0.029, 0.061) |
|
| TSS200 | |||||
| cg10149123 | 16 |
| Body | –2.231 | 1.28 × 10–05 | –0.277 (–0.377, –0.177) |
| cg16493531 | 6 |
| TSS1500 | –1.979 | 1.45 × 10–05 | –0.424 (–0.580, –0.267) |
|
| Body | |||||
| cg23528705 | 7 |
| Body | 1.600 | 1.50 × 10–05 | 0.075 (0.059, 0.098) |
| cg02297831 | 4 |
| TSS200 | –1.948 | 1.55 × 10–05 | –0.025 (–0.038, –0.013) |
| Trimesters 1 and 2 combined | ||||||
| CpG site | Chr | Gene | Location | M coefficient |
| β coefficient (95% CI) |
| cg18705808 | 7 |
| Body | 1.375 | 1.93 × 10–08 | 0.025 (0.015, 0.036) |
| cg13898459 | 19 |
| TSS1500 | 11.017 | 5.00 × 10–07 | 1.328 (0.762, 1.893) |
| cg13852093 | 18 |
| Body | 16.052 | 1.52 × 10–06 | 2.189 (1.491, 2.887) |
| cg17706097 | 10 | Intergenic | Intergenic | 1.949 | 1.97 × 10–06 | 0.312 (0.182, 0.443) |
| cg11931463 | 3 | Intergenic | Intergenic | 1.981 | 4.02 × 10–06 | 0.411 (0.239, 0.584) |
| cg09308091 | 10 |
| Body | 1.572 | 4.62 × 10–06 | 0.301 (0.178, 0.424) |
| cg14305641 | 19 |
| 3′ UTR | 3.704 | 4.77 × 10–06 | 0.192 (0.096, 0.288) |
| cg25799969 | 2 |
| 5′ UTR; 1st Exon | 3.657 | 7.03 × 10–06 | 0.847 (0.540, 1.155) |
| cg27117509 | 2 |
| 3′ UTR | 3.479 | 7.55 × 10–06 | 0.181 (0.098, 0.265) |
| cg26020805 | 18 |
| Body | 2.950 | 7.94 × 10–06 | 0.249 (0.147, 0.351) |
aSites in both top 10 of trimester 1 and combined EWAs.
bSite found to be significant after FDR correction.
cRegression parameter from EWAs on DNAm m-value corresponding an increase in 10 μg/m3 of PM2.5.
dRegression parameter from EWAs on DNAm β-value corresponding an increase in 10 μg/m3 of PM2.5 Pathway and Network Analysis.
CI indicates confidence interval.
Top pathways and networks enriched by genes regulated by top CpG sites using IPA
| Trimester 1 | |
|---|---|
| Top canonical pathways | –log10( |
| 5-aminoimidazole ribonucleotide biosynthesis I | 2.62 |
| Purine nucleotides de novo biosynthesis II | 2.06 |
| DNA methylation and transcriptional repression signaling | 1.56 |
| Dermatan sulfate biosynthesis (late stages) | 1.43 |
| Chondroitin sulfate biosynthesis (late stages) | 1.41 |
| Top networks | Score |
| Cancer, cardiac necrosis/cell death, cell death and survival | 23 |
| Cancer, cellular compromise, organismal injury and abnormalities | 23 |
| Trimester 2 | |
| Top canonical pathways | –log10( |
| Iron homeostasis signaling pathway | 1.94 |
| Human embryonic stem cell pluripotency | 1.79 |
| Circadian rhythm signaling | 1.4 |
| Complement system | 1.37 |
| G protein signaling mediated by tubby | 1.3 |
| Top networks | Score |
| Infectious diseases, cell-to-cell signaling and interaction, renal and urological system development and function | 26 |
| Cellular response to therapeutics, cell-to-cell signaling and interaction, nervous system development and function | 20 |
| Embryonic development, organismal development, gene expression | 20 |
| Trimesters 1 and 2 | |
| Top canonical pathways | –log10( |
| Wnt/Ca+ pathway | 2.63 |
| Wound healing signaling pathway | 2.59 |
| Insulin secretion signaling pathway | 2.5 |
| Pulmonary fibrosis idiopathic signaling pathway | 2.28 |
| Neuropathic pain signaling in dorsal horn neurons | 2.27 |
| Top networks | Score |
| Lipid metabolism, small molecule biochemistry, cell cycle | 27 |
| Cell death and survival, connective tissue development and function, cellular movement | 24 |
| RNA damage and repair, protein synthesis, infectious diseases | 4 |
| Developmental disorder, hereditary disorder, ophthalmic disease | 2 |
Scores for top networks represent a ranking of the networks least likely to be generated by chance with scores over 2 denoting a 99% likelihood of not being generated by chance.